To observe the effect of Siddha formulation Kabasura kudineer in COVID 19 patients
Phase 2
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/06/025874
- Lead Sponsor
- Dean Government Theni Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Laboratory confirmed COVID-19 without symptoms
2.Consenting to participate in the study and sign the informed consent
Exclusion Criteria
1.Patient with co morbid conditions like DM, HT and BA.
2.Patients with severe primary respiratory disease or other pathogenic microbial pneumonia that needs to be identified with COVID-19.
3.Pregnant and mothers those who have a pregnancy plan.
4.Patients with other systemic malignant diseases such as malignant tumors, mental illnesses, etc., which the researchers consider unsuitable for participation in the study.
5.People who have been allergic to Siddha medicine or intolerant to taking medicine.
6.Patients participating in other COVID-19 clinical trials.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Reduction in incidence of clinical symptoms like fever, cough and breathlessness. <br/ ><br>2.Negative conversion of SARS-CoV-2 by 14 days <br/ ><br>3.Reduction in Viral load of SARS-CoV-2 at the end of treatment (0, 7, 14 days) <br/ ><br>4.Examine the levels of immune markers and inflammatory markers (IgG, IgM, IgA, Th1 (TNF-Alfa, IFN-gamma, IL2) Th2 (IL6, IL10) at the end of treatment (0, 7, 14 days) <br/ ><br>Timepoint: 14 days
- Secondary Outcome Measures
Name Time Method 1.Reduction in incidence of complications. <br/ ><br>2.Reduction of in hospital time. <br/ ><br>3.Laboratory markers <br/ ><br>4.Adverse events/effects <br/ ><br>Timepoint: 14 days